Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2135-2140

  Cheng, Liang ^a,b   Zhang, Shaobo ^a   Sweeney, Christopher J ^a   Kao, Chinghai ^a   Gardner, Thomas A ^a   Eble, John N ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Androgen independent; Angiogenesis; Animal models; CWR22; Prostate; VEGF

Indexed keywords

ANDROGEN; BLOOD CLOTTING FACTOR 8; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER CELL LINE CWR22RV1; CANCER MODEL; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

ANDROGENS; ANIMALS; CELL DIVISION; HUMANS; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4444290677     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED and Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymph adenectomy in men with node positive prostate cancer. New Engl J Med 341: 1781-1788, 1999.
2. Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer BG and Bostwick DG: Risk of prostate cancer death in patients with lymph node metastasis. Cancer 91: 66-73, 2001.
3. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, Chamberlain M, Webster A and Blackledge G: A randomized comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33: 447-456, 1998.
4. Chang A, Yeap B, Davis T, Blum R, Hahn R, Kaanna O, Fisher H, Rosenthal J, Witte R, Schinella R et al: Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 14: 2250-2257, 1996.
5. Folkman J: The role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18, 2002.
6. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
7. Folkma J: Tumor angiogenesis and tissue factor. Nat Med 2: 167-168, 1996.
8. Kong H and Crystal RG: Gene therapy strategies for tumor antiangiogenesis. J Nat Cancer Inst 90: 273-286, 1998.
9. Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F and Keshet E: Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95: 10820-10825, 1998.
10. Sugamoto T, Tanji N, Sato K, Fujita H, Nishio S, Sakanaka M and Yokoyama M: The expression of basic fibroblast growth factor and vascular endothelial growth factor in prostatic adenocarcinoma: correlation with neovascularization. Anticancer Res 21: 77-88, 2001.
11. Joseph IB, Nelson JB, Denmeade SR and Isaacs JT: Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 12: 2507-2511, 1997.
12. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A and Biagini G: Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 45: 72-79, 2000.
13. Stewart RJ, Panigrahy D, Flynn E and Folkman J: Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 165: 688-693, 2001.
14. Sordello S, Bertrand N and Plouet J: Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun 251: 287-290, 1998.
15. Kwak C, Jin RJ, Lee C, Park MS and Lee SE: Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia. BJU Int 89: 303-309, 2002.
16. Haggstrom S, Wikstrom P, Bergh A and Damber JE: Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate 36: 71-80, 1998.
17. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D and Jacobberger JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol 35: 403-409, 1999.
18. Kim D, Gregory CW, French FS, Smith GJ and Mohler JL: Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol 160: 219-226, 2002.
19. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL and French FS: Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58: 5718-5724, 1998.
20. Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL and French FS: Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology 140: 2372-2381, 1999.
21. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schartz S, Kung HJ, White RW, Gumerlock PH, Resnick MI et al: CWR22: The first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56: 3042-3046, 1996.
22. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED et al: CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 54: 6049-6052, 1994.
23. Gleave M, Hsieh JT, Gao C, von Eschenbach AC and Chung LWK: Acceleration of human prostate cancer in vivo by factors produced by prostate and bone fibroblast. Cancer Res 51: 3753-3761, 1991.
24. Zhang S, Zeng G, Kao C, Gardner TA, Sweeney CJ, Yang NS, Eble JN and Cheng L: Fas-Fas ligand signaling pathway mediates an interleukin-12 induced rejection of a murine prostate tumor system. Prostate 53: 69-76, 2002.
25. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
26. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AI, Schere BG, Blute ML, Zincke H and Bostwick DG: Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res 5: 2820-2823, 1999.
27. Franck-Lissbrant I, Haggstrom S, Damber JE and Bergh A: Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139: 4672-4678, 1998.
28. Richard C, Kim G, Koikawa Y, Salm SN, Tsujimura A, Wilson EL and Moscatelli D: Androgens modulate the balance between VEGF and angiopoietin expression in prostate epithelial and smooth muscle cells. Prostate 50: 83-91, 2002.